VTRS stock news · Viatris Inc.
Get alerts for VTRS
Follow Viatris Inc. (VTRS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VTRSViatris is hosting the CV Masterclass 2026 in the Philippines to tackle heart disease issues.
NeutralViatris hosted a heart-health meeting in the Philippines and shared care ideas. The event shows outreach, but reports no new business results, so it does not change the outlook for Viatris.
Viatris Korea has been named one of the top places to work in Asia.
NeutralViatris Korea was named among Asia's best workplaces, recognizing its efforts to support employees. The story reports no change to Viatris's business results, so it does not change the company's outlook.
Viatris is spending a lot of money to buy Pacira, which makes non-opioid pain medicines.
Good for VTRSViatris agreed to buy Pacira for $1.65 billion, adding 2 established pain treatments. Expected added profit supports a positive reading, though the deal uses cash and borrowing and still needs approvals.
Pacira BioSciences, Inc. has agreed to merge with Viatris Inc. in a big deal.
NeutralViatris agreed to buy Pacira for $36.50 per share, subject to tender and regulatory conditions. The filing gives no expected gains, costs, or funding details, so it does not show a clear change to Viatris's business outlook.
Harrow, Inc. has finalized a big deal to buy TYRVAYA nasal spray for $30 million.
NeutralViatris received $30 million and may receive up to $70 million more if sales targets are met. It gave up TYRVAYA rights outside Japan and owes Harrow royalties on Japanese sales, so the deal's gains and costs point in different directions.
Viatris enhances strategic direction through divestment, raises 2026 projections.
NeutralViatris has announced a divestiture of its Tyrvaya nasal spray to Harrow for up to $100 million, alongside a strong Q2 earnings report that exceeded expectations. The company has also raised its guidance for 2026, reflecting confidence in its strategic direction and operational execution.